The FDA approved Moderna’s flu vaccine mFLUSIVA, a regulatory decision that comes six months after the agency refused to review the mRNA shot and then quickly reversed its position. But a recommendation from a Centers for Disease Control and Prevention advisory committee is key for payer coverage, and that committee has not met all year due to ongoing litigation.
The post Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain appeared first on MedCity News.
